Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Publikováno v:
Journal of the National Cancer Institute. 109(5)
Background Recent studies have suggested associations between statins and enhanced survival among patients with pancreatic ductal adenocarcinoma (PDAC). However, the relationship between statins, cholesterol, and survival remains unclear. Methods We
Autor:
Kohichi Takada, Satoshi Iyama, Makoto Yoshida, Masahiro Hirakawa, Koji Miyanishi, Takahiro Osuga, Fumito Tamura, Yutaka Okagawa, Naoki Uemura, Yohei Arihara, Junji Kato, Masayoshi Kobune, Tsutomu Sato, Tsuyoshi Hayashi, Rishu Takimoto, Yasushi Sato, Michihiro Ono
Publikováno v:
Journal of the National Cancer Institute. 108(8)
BACKGROUND Fucose is utilized for the modification of different molecules involved in blood group determination, immunological reactions, and signal transduction pathways. We have recently reported that enhanced activity of the fucosyltransferase 3 a
Autor:
Stephen R. D. Johnston
Publikováno v:
Journal of the National Cancer Institute. 107(10)
Overcoming primary or secondary endocrine resistance in breast cancer remains critical to further enhancing the benefit of existing therapies such as tamoxifen or an aromatase inhibitor (AI). Much progress has been made in understanding the molecular
Autor:
Klaus Kaae Andersen, Christian Dehlendorff, Jørgen H. Olsen, Louise Baandrup, Susanne K. Kjaer, Søren Friis
Publikováno v:
Journal of the National Cancer Institute. 106(6)
It has been suggested that paracetamol reduces the risk for ovarian cancer. We examined the association between prescription use of paracetamol and ovarian cancer risk in a nationwide case–control study nested within the Danish female population. C
Autor:
Olivier Mir, Gilbert Deray, Luc Mouthon, Jérôme Alexandre, François Goldwasser, Loïc Guillevin, Jean-Michel Mallion
Publikováno v:
Journal of the National Cancer Institute. 99(1)
Autor:
Thomas G. O'Brien, Robert W. Haile, Carol A. Burke, Elizabeth L. Barry, Robert S. Sandler, Dennis J. Ahnen, Maria V. Grau, John A. Baron, Shubha Bhat
Publikováno v:
Journal of the National Cancer Institute. 98(20)
Background: Previous research suggests that the G315A singlenucleotide polymorphism in the ornithine decarboxylase (ODC) gene may be a genetic marker for risk of colorectal neoplasia and may also modify the association of aspirin use with risk. Metho
Autor:
Béatrice Weber, Andreas du Bois, Walther Kuhn, W. Schröder, A. Stähle, Hugues Bourgeois, Jens-Uwe Blohmer, Volker Möbus, Gineco, Alain Lortholary, Barbara Richter, SD Costa, Jean-François Geay, Rainer Kimmig, Jacobus Pfisterer, Werner Meier, Anne-Claire Hardy-Bessard, Christian Jackisch, Uwe Wagner, Alexander Reuss, Jens Quaas, S. Olbricht, Hans-Joachim Lück, Harald Meden, Eric Pujade-Lauraine, Ulrike Nitz
Publikováno v:
Journal of the National Cancer Institute. 98(15)
BACKGROUND The combination of carboplatin and paclitaxel is the standard of care for the treatment of ovarian cancer, yet rates of recurrence and death remain high. We performed a prospective randomized phase III study to examine whether sequential a
Publikováno v:
Journal of the National Cancer Institute. 97(9)
Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer Background. Recent dose-intensity studies of small-cell lung cancer (SCLC) have yielded conflicting re
Autor:
Dorothy K. Hatsukami, Steven G. Carmella, Sharon E. Murphy, Stephen S. Hecht, Yan Zhang, Chap T. Le, Charlotte Lemmonds
Publikováno v:
Journal of the National Cancer Institute. 96(11)
Background: Although tobacco products with reportedly reduced carcinogen content are being marketed, carcinogen uptake in people who use these products has not been assessed systematically. Methods: Between June 2001 and November 2002, 54 users of sm
Autor:
Daniel F. Hayes, Antonella Novielli, James M. Rae, Vered Stearns, Michael D. Johnson, David A. Flockhart, Zeruesenay Desta, Alan Morocho, Pankaj Bhargava
Publikováno v:
Journal of the National Cancer Institute. 95(23)
Background: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes. Selective serotonin reuptake inhibitors (SSRIs), which are often prescribed to a